A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation

키워드

참고문헌 (52)

1. Alzheimer's Association, "2017 Alzheimer's disease facts and figures", Alzheimers Dement, 13, pp.325~373 (2017)
2. Global Action Plan on the Public Health Response to Dementia 2017–2025, "World Health Organization", World Health Organization, ~ (2017)
3. The Epidemiology and Impact of Dementia : Current State and Future Trends, "Prince M", World Health Organization, ~ (2015)
4. Korean Dementia Observatory 2016, "National Institute of Dementia", National Institute of Dementia, ~ (2017)
5. Karantzoulis S, "Distinguishing Alzheimer's disease from other major forms of dementia", Expert Rev Neurother, 11, pp.1579~1591 (2011)
6. McManus RM, "Role of neuroinflammation in neurodegeneration: new insights", Alzheimers Res Th, 9, pp.14~ (2017)
7. Mayeux R, "Heterogeneity in dementia of the Alzheimer type: evidence of subgroups", Neurology, 35, pp.453~461 (1985)
8. Yiannopoulou KG, "Current and future treatments for Alzheimer's disease", Ther Adv Neurol Disorder, 6, pp.19~33 (2013)
9. Zhao X, "A novel drug discovery strategy inspired by traditional medicine philosophies", Science, 347, pp.S38~S40 (2015)
10. Herrup K, "Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease", Alzheimers Dement, 9, pp.452~458.e1 (2013)
11. Hampel H, "Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification", Front Neuroendocrinol, 50, pp.31~51 (2018)
12. Hampel H, "Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology", J Alzheimers Dis, 64, pp.S47~S105 (2018)
13. Cummings JL, "Alzheimer's disease drug-development pipeline: few candidates, frequent failures", Alzheimers Res Ther, 6, pp.37~ (2014)
14. Morgan P, "Impact of a five-dimensional framework on R&D productivity at AstraZeneca", Nat Rev Drug Discov, 17, pp.167~181 (2018)
15. Finger E, "Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)", Alzheimers Res Ther, 10, pp.102~ (2018)
16. Lam B, "Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome", Alzheimers Res Ther, 5, pp.1~ (2013)
17. Schmidt C, "Rapidly progressive Alzheimer disease", Arch Neurol, 68, pp.1124~1130 (2011)
18. "Pharma 2020: the vision. Which path will you take?" (2007)[URL]
19. Pallmann P, "Adaptive designs in clinical trials: why use them, and how to run and report them", BMC Med, 16, pp.29~ (2018)
20. Heneka MT, "Innate immune activation in neurodegenerative disease", Nat Rev Immunol, 14, pp.463~477 (2014)
21. Hooten KG, "Protective and toxic neuroinflammation in amyotrophic lateral sclerosis", Neurotherapeutics, 2, pp.364~375 (2015)
22. Heneka MT, "Neuroinflammation in Alzheimer's disease", Lancet Neurol, 14, pp.388~405 (2015)
23. Kettenmann H, "Physiology of microglia", Physiol Rev, 91, pp.461~553 (2011)
24. Hashimoto D, "Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes", Immunity, 38, pp.792~804 (2013)
25. Nimmerjahn A, "Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo", Science, 308, pp.1314~1318 (2005)
26. Keren-Shaul H, "A unique microglia type associated with restricting development of Alzheimer's disease", Cell, 169, pp.1276~1290 (2017)
27. Deczkowska A, "Disease-associated microglia: a universal immune sensor of neurodegeneration", Cell, 173, pp.1073~1081 (2018)
28. Michell-Robinson MA, "Roles of microglia in brain development, tissue maintenance and repair", Brain, 138, pp.1138~1159 (2015)
29. Andreasson KI, "Targeting innate immunity for neurodegenerative disorders of the central nervous system", J Neurochem, 138, pp.653~693 (2016)
30. Song GJ, "Pharmacological modulation of functional phenotypes of microglia in neurodegenerative diseases", Front Aging Neurosci, 9, pp.139~ (2017)
31. Malik M, "Genetics ignite focus on microglial inflammation in Alzheimer's disease", Mol Neurodegener, 10, pp.52~ (2015)
32. Noh MY, "Mesenchymal stem cells modulate the functional properties of microglia via TGF-β secretion", Stem Cells Transl Me, 5, pp.1538~1549 (2016)
33. Bianchin MM, "Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy--PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects", Cell, 24, pp.1~24 (2004)
34. Hickman SE, "TREM2 and the neuroimmunology of Alzheimer's disease", Biochem Pharmacol, 88, pp.495~498 (2014)
35. Wang Y, "TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model", Cell, 160, pp.1061~1071 (2015)
36. Slattery CF, "R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia", Alzheimers Dement, 10, pp.602~608.e4 (2014)
37. Cady J, "TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis", JAMA Neurol, 71, pp.449~453 (2014)
38. Palmqvist S, "Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography", Brain, 139, pp.1226~1236 (2016)
39. Suárez-Calvet M, "sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers", EMBO Mol Med, 8, pp.466~476 (2016)
40. David S, "Repertoire of microglial and macrophage responses after spinal cord injury", Nat Rev Neurosci, 12, pp.388~399 (2011)
41. Desikan RS, "Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score", PLoS Med, 14, pp.e1002258~ (2017)
42. Seshadri S, "Genome-wide analysis of genetic loci associated with Alzheimer disease", JAMA, 303, pp.1832~1840 (2010)
43. Boillée S, "Onset and progression in inherited ALS determined by motor neurons and microglia", Science, 312, pp.1389~1392 (2006)
44. Zhao W, "Characterization of gene expression phenotype in ALS monocytes", JAMA Neurol, 74, pp.677~685 (2017)
45. Frakes AE, "Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis", Neuron, 81, pp.1009~1023 (2014)
46. (R)-PK11195 positron emission tomography study, "Neurobiol Dis", 2004, 601~609
47. Beers DR, "Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis", Proc Natl Acad Sci U S A, 103, pp.16021~16026 (2006)
48. Komine O, "Neuroinflammation in motor neuron disease", Nagoya J Med Sci, 77, pp.537~549 (2015)
49. Spiegel S, "The outs and the ins of sphingosine-1-phosphate in immunity", Nat Rev Immunol, 11, pp.403~415 (2011)
50. Nayak D, "Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia", Neuroscience, 166, pp.132~144 (2010)
51. Lee JY, "Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's disease", Nat Commun, 9, pp.1479~1497 (2018)
52. Pchejetski D, "The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6", Immunol Cell Biol, 89, pp.268~274 (2011)

관련 논문AI추천